news
Cognito 40 Hz Light Therapy Slows Early Alzheimer's Decline
Cognito Therapeutics presented Phase 2 data at CTAD Boston showing that an hour daily of 40-hertz light and sound slowed functional decline by 80% in early Alzheimer's patients who stuck with treatment. The broader trial missed statistical significance across all stages, dividing neurologists on whether the effect is genuine. It remains the largest human test of sensory brain entrainment to date.
Cognito Therapeutics presented Phase 2 data at CTAD Boston showing that an hour daily of 40-hertz light and sound slowed functional decline by 80% in early Alzheimer's patients who stuck with treatment. The broader trial missed statistical significance across all stages, dividing neurologists on whether the effect is genuine. It remains the largest human test of sensory brain entrainment to date.
The architecture take
Gamma wave entrainment sounds like something an expensive biohacking studio sells you between cold plunges. I used to brush off the 40-hertz strobe papers as rodent curiosities until Cognito ran this clinical trial. The biology relies on driving visual and auditory cortex neurons to fire synchronously at 40 cycles per second, which prompts microglia, the brain's resident cleaning crew, to clear amyloid plaques and calm neuroinflammation before tissue dies. The catch is the window. If neurodegeneration has already destroyed large swathes of cortex, flashing goggles cannot revive silent circuits. That explains why the broad trial cohort fell flat while compliant, mild-stage patients held steady. Watch consumer hardware brands quietly copy this protocol with cheap LED flicker glasses and binaural tracks before the FDA finishes reviewing Cognito's hardware. When an intervention shows an 80 percent retention of daily function in early disease, families won't wait three years for regulatory paperwork.